Home / Biosimilars / Research / Biosimilars - to switch or not to switch

Biosimilars - to switch or not to switch Posted 25/01/2019

Switching V19A17

Authors Marc Scherlinger and Thierry Schaeverbeke commented on the paper from Glintborg and co-authors ‘To switch or not to switch’ ,which reported the results of biosimilar etanercept switching in Denmark [1].

In April 2016, Denmark implemented a national guideline mandating non-medical switching of all patients treated with the originator etanercept Enbrel to biosimilar etanercept, Benepali (SB4).

However, one year later, out of a total of 2,030 patients treated with etanercept identified in the nationwide quality registry, DANBIO, only 1,623 (80%) had been switched to Benepali [2]. This means that 20% of patients were still being treated with Enbrel. 

Scherlinger and Schaeverbeke point out that there are two strategies for switching patients from more expensive originator biologicals to biosimilars, with their 20%‒50% lower costs, either a shared decision or a mandatory switch.

Switching to a biosimilar via a physician–patient shared decision has, according to the authors, been favoured by rheumatology scientific societies, by an international consensus group and by patient associations. In fact, they point out that real-life studies reporting the acceptance of switching from Enbrel to SB4 using shared decision and communication have reported acceptance rates of 92–99%. In addition, Scherlinger and Schaeverbeke say that there is evidence suggesting that forcing the switch on a patient is likely to increase the risk of the nocebo effect, having a negative effect on the patient and on the physician–patient relationship. This nocebo effect could cause a need for a switch back or possibly the need to switch to another originator biological.

The authors conclude that ‘considering this body of evidence’, they ‘believe that Glintborg’s study was the missing piece in the puzzle of the biosimilars literature, demonstrating that a mandatory switch is probably not the most efficient strategy for the wide diffusion of biosimilar in chronic rheumatic diseases and reinforcing the evidence of the necessity of a shared physician–patient decision as recommended by many’.

Conflict of interest
The authors of the research paper [1] declared that there was no conflict of interest. 

Related articles
Long-term follow-up of switching to biosimilar infliximab

Switching to etanercept biosimilar SB4 safe and effective in a hospital setting

References
1. Scherlinger M, Schaeverbeke T. ‘To switch or not to switch’: the missing piece in the puzzle of biosimilar literature? Ann Rheum Dis. 2019; Jan 4. pii: annrheumdis-2018-214908. doi: 10.1136/annrheumdis-2018-214908. [Epub ahead of print]
2. GaBI Online - Generics and Biosimilars Initiative. Danish etanercept switching study investigates withdrawal rates [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Jan 25]. Available from: www.gabionline.net/Biosimilars/Research/Danish-etanercept-switching-study-investigates-withdrawal-rates

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

Comments (0)